Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-07-29 Board/Management Inform…
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
General Updates
Board/Management Information Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the outcome of a Board Meeting held on July 29, 2025. It reports the re-appointment of the internal auditors and the grant of stock options to employees. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events by listed companies. The content is an announcement of decisions made by the Board rather than a full report or detailed financial statements. It includes annexures providing details about the auditor re-appointment and stock option grants, but these are disclosures related to corporate governance and stock option plans, not comprehensive financial or management reports. The document is relatively short (5983 characters) and serves as an official announcement of board decisions and related disclosures. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-07-29 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 90% confidence The document is an official stock exchange filing by Jubilant Pharmova Limited under SEBI Listing Regulations 30 and 33, announcing the Board meeting outcome where the Board approved the unaudited standalone and consolidated Financial Results for the quarter ended June 30, 2025, and includes the full interim financial statements with notes and the Limited Review Report by the independent auditor. It therefore constitutes the actual interim (quarterly) financial report, not merely an announcement. This matches the definition of an Interim / Quarterly Report (Code: IR). Q1 2026
2025-07-29 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the outcome of a postal ballot. It references Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides detailed voting results and a scrutinizer's report for a special resolution. The content focuses on the announcement of voting results from a shareholder postal ballot rather than the full details of the resolution or financial data. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA). The document length and detail support this classification with high confidence.
2025-07-24 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchanges about an upcoming Board Meeting scheduled for July 29, 2025. The purpose of the meeting is to consider the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The document references Regulation 29 of the SEBI Listing Regulations, which governs disclosures related to board meetings. The document does not contain any financial data or results itself, nor does it include detailed financial analysis or management discussion. It is an announcement of a board meeting date and agenda, not the financial report or results. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about a board meeting and upcoming financial results, but not the results or report itself.
2025-07-23 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-07-23 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details an investment and acquisition of shares in Isharays Energy Two Private Limited by Jubilant Pharmova Limited. The content includes specifics about the acquisition, such as the percentage of shares acquired, consideration, background of the target entity, and terms of the agreement. This type of disclosure is typical of a Capital/Financing Update as it relates to investment and share subscription activities. The document is not a full financial report, earnings release, or management discussion, but rather an update on a financing/investment transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9026 characters) and detailed content support this classification with high confidence.
2025-07-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.